CLINICAL AND REAL-WORLD EVIDENCE IN TYPE 1 AND TYPE 2 DIABETES PATIENTS

FACTS SPEAK FOR THEMSELVES

Simulated data for illustrative purposes only. Not real patient or data. 1. Scanning the sensor does not require lancets. This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
The FreeStyle Libre system is proven to result in better clinical outcomes

- Improves Quality of Life

- Decreases Work Absenteeism

- Decreases Hospital Admissions

- Decreases A1c

- Increases Time In Range

- Reduces Hypoglycaemia

- Decreases A1c

Product image for illustrative purposes only. Not real patient data.


This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
The FreeStyle Libre system significantly increases Time In Range¹

Every 5% (~1 hour per day) increase in Time In Range is associated with clinically significant benefits²

Real-world data reinforce more frequent use of the FreeStyle Libre system increases Time In Range

Comparing 2 groups from lowest to highest scan rate, patients who scanned more frequently using the FreeStyle Libre system spent 43% more Time In Range.

Frequent use of the FreeStyle Libre system also resulted in patients spending 26% less Time Below Range (<3.0 mmol/L)


2. Comparing 2 groups from lowest to highest scan rate (3.6 and 39.5 scans/day). This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
The FreeStyle Libre system is clinically proven to significantly reduce hypoglycaemia in T1D patients.

A 6-month RCT in 328 well-controlled T1D patients (with baseline A1c ≤7.5%) proves the FreeStyle Libre system safely and successfully replaces SMBG.

- Reduces nocturnal hypoglycaemia (<3.9 mmol/L, time in hour, from 11:00 pm to 6:00 am) (p<0.0001)
- Reduces serious hypoglycaemia (<3.1 mmol/L, time in hour, within 24 hours) (p<0.0001)

Significantly reduces time spent in hypoglycaemia (<3.9 mmol/L)

<table>
<thead>
<tr>
<th>Minutes/day</th>
<th>SMBG (Control)</th>
<th>FreeStyle Libre system</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>196</td>
<td>122 (p&lt;0.0001)</td>
</tr>
</tbody>
</table>

-38% reduction

This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
The FreeStyle Libre system is clinically proven to significantly reduce hypoglycaemia in T2D patients

A 6-month RCT in 224 T2D patients on intensive insulin therapy proves the FreeStyle Libre system safely and successfully replaces SMBG.

**FACT**

Type 2D Replace Study

- **Significantly reduces time spent in hypoglycaemia (<3.9 mmol/L)**
  - SMBG (Control): 65 minutes/day
  - FreeStyle Libre system: 37 minutes/day

- **Reduces nocturnal hypoglycaemia**
  - (p=0.0001)
  - FreeStyle Libre system: 54%

- **Reduces serious hypoglycaemia**
  - (p=0.0014)
  - FreeStyle Libre system: 53%

---

RCT=randomised controlled trial; SMBG=self-monitored blood glucose; T2D=type 2 diabetes mellitus.

1. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
The FreeStyle Libre system demonstrates clinically significant A1c reductions\(^1\)

In a 10-week RCT, T2D patients on MDI (n=101) using the FreeStyle Libre system saw a significant A1c reduction compared to SMBG (0.82% vs 0.33%, respectively).

\[ \text{A1c} \downarrow \quad 0.82\% \quad (p=0.005) \]

More than \(2X\) as many patients using the FreeStyle Libre system reduced their A1c by 0.5% at week 10 versus SMBG.

FreeStyle Libre system vs SMBG

\[ \begin{align*}
68.6\% & \quad \text{(p<0.001)} \\
30.2\% & \quad \text{SMBG}
\end{align*} \]

The FreeStyle Libre system reduces A1c without increasing the frequency of hypoglycaemia\(^1\)

RCT=randomised controlled trial; T2D=type 2 diabetes mellitus; MDI=multiple daily insulin injections; SMBG=self-monitored blood glucose.


This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
A1c reduction is sustained with the FreeStyle Libre system¹

This A1c reduction was observed at 2-4 months and sustained at month 12 in adults and children with T1D and adults with T2D.

2. NOTE: statistically significant A1c reduction based on the confidence interval range.

---

T1D=type 1 diabetes mellitus; T2D=type 2 diabetes mellitus.

This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
Real-world data show that the use of the FreeStyle Libre system improves quality of life\(^1\)

- **95%** report a better understanding of their glucose fluctuations
- **92%** find it easier to regulate their glucose around a meal
- **80%** adjust insulin doses more frequently
- **37%** report engaging in physical activity more frequently

A RWD study of the effect of the FreeStyle Libre system on 1365 T1D and T2D patients on insulin over 1 year. Endpoints included A1c, hypoglycaemia, and patient-reported outcomes.

---


This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
Real-world data demonstrate that the use of the FreeStyle Libre system decreases diabetes-related hospital admissions\textsuperscript{1,2}

**FACT**

A RWD study of the effect of the FreeStyle Libre system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes

**66% reduction in hospital admissions**
from 13.7% to 4.7% at 12 months

\[(p<0.05)\]

A RWD study of the effect of the FreeStyle Libre system on 1913 T1D patients at 6 months and 1 year: endpoints included quality of life, number of hospital admissions, and hypoglycaemia

**33% reduction in DKA or hypo admissions**
from 3.3% to 2.2% at 12 months

\[(p=0.031)\]

RWD=real-world data/observational study; T1D=type 1 diabetes mellitus; T2D=type 2 diabetes mellitus; DKA=diabetic ketoacidosis; hypo=hypoglycaemia.


\textsuperscript{2}Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. *Diabetes Care*. 2020;43(2):389-397. This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
Real-world data demonstrate that the use of the FreeStyle Libre system decreases work absenteeism¹.

A RWD study of the effect of the FreeStyle Libre system on 1365 T1D and T2D patients on insulin over 1 year: endpoints included A1c, hypoglycaemia, and patient-reported outcomes.

A similar reduction in work absenteeism was observed in patients under 65 years from 20.4% to 8.3% (p<0.001).

Reduction in work absenteeism from 18.5% to 7.7% at 12 months (p<0.05)

FLARE STUDY²


This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.
FreeStyle Libre system is the #1 sensor-based glucose monitoring system worldwide\(^1,2\)

**FACTS SPEAK FOR THEMSELVES**

- Increases Time In Range\(^3\)
- Reduces Hypoglycaemia\(^3,4\)
- Decreases A1c\(^5\)
- Improves Quality of Life\(^6\)
- Decreases Hospital Admissions\(^6,7\)
- Decreases Work Absenteeism\(^6\)

**Recommend the FreeStyle Libre system to all T1D and T2D patients using insulin**

Product image for illustrative purposes only. Not real patient data. T1D=type 1 diabetes mellitus; T2D=type 2 diabetes mellitus.


This material is specific for the EASD meeting. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.

© 2020 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. ADC:27048 V1.0. 09/20.